Schimmelpennink Evert B.
SEC CIK 1713795 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| LENZ | LENZ Therapeutics, Inc. | Pres, CEO, Sec, Dir | 77.3K | $251.4K | — | 3 | 2024-07-22 | 2026-03-27 |
Most active insiders at LENZ, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Versant Vantage II GP-GP, LLC | 10% | — | $10.35M |
| 2 | Olsson Shawn | Chief Commercial Off | — | $261.0K |
| 3 | Schimmelpennink Evert B. | Pres, CEO, Sec, Dir | $251.4K | — |
| 4 | MCCOLLUM JAMES W | Dir | $239.3K | — |
| 5 | Chevallard Daniel R. | CFO | $114.3K | — |
| 6 | George Jeffrey P. | Dir | $49.9K | — |
Transactions 3
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-30 | 2026-03-27 | LENZ | LENZ Therapeutics, Inc. | Schimmelpennink Evert B. | Pres, CEO, Sec, Dir | P - Purchase | $8.95 | +28.1K | 77.3K | +57% | +$251.4K | |
| D | 2025-03-07 | 2025-03-07 | LENZ | LENZ Therapeutics, Inc. | Schimmelpennink Evert B. | Pres, CEO, Sec, Dir | M - OptEx | $1.04 | +4,200 | 49.2K | +9% | +$4,368 |
| D | 2024-07-23 | 2024-07-22 | LENZ | LENZ Therapeutics, Inc. | Schimmelpennink Evert B. | Pres, CEO, Sec, Dir | M - OptEx | $1.04 | +45.0K | 45.0K | New | +$46.8K |
Purchase Sale Sale after option exercise All abbreviations